Safain Mina G, Roguski Marie, Heller Robert S, Malek Adel M
From the Cerebrovascular and Endovascular Division, Department of Neurosurgery, Tufts Medical Center and Tufts University School of Medicine, Boston, MA.
Stroke. 2016 Mar;47(3):789-97. doi: 10.1161/STROKEAHA.115.010522. Epub 2016 Jan 28.
Flow diversion using the Pipeline Embolization Device is reported as a safe treatment of aneurysms. Complete aneurysm occlusion, however, occurs in a delayed fashion with initial persistent filling of the aneurysm dome. We hypothesized that this transflow across metallic struts may be associated with thromboembolic events.
Forty-one consecutive patients undergoing aneurysm treatment with the Pipeline Embolization Device and a comparison group of 78 Neuroform stent-mediated embolizations were studied. Patients' charts, procedure notes, platelet function, and anticoagulation state were analyzed. Serial magnetic resonance images were assessed for the presence of newly occurring diffusion-weighted imaging and fluid-attenuated inversion recovery (FLAIR) lesions at multiple postprocedure time ranges (average days post procedure [Pipeline Embolization Device/Neuroform]: T1=1, T2=73/107, T3=174, T4=277/335, and T5=409). In addition, diffusion-weighted imaging or FLAIR burden was estimated by lesional diameter summation.
Pipeline patients were more likely to have new ipsilateral FLAIR lesions at all time points studied (30.6% versus 7.2% of patients at T=2 and 34.5% versus 6.2% at T=4). The mean FLAIR burden was significantly increased for Pipeline patients (10.1 versus 0.7 mm at T=2 and 8.8 versus 1.9 mm at T=4). Overall 34% (14/41) of Pipeline patients experienced a new FLAIR lesion at anytime when compared with 10% (8/78) of Neuroform stent-coil patients. Postprocedural diffusion-weighted imaging did not predict future FLAIR lesions suggesting a nonprocedural cause.
The Pipeline Embolization Device is associated with increased rate of de novo FLAIR lesions occurring in a delayed fashion and distinct from perioperative diffusion-weighted imaging lesions. The cause and clinical effect of these lesions are unknown and suggest the need for prudent follow-up and evaluation.
据报道,使用Pipeline栓塞装置进行血流导向是一种安全的动脉瘤治疗方法。然而,动脉瘤完全闭塞是一个延迟过程,最初动脉瘤瘤顶持续显影。我们推测,这种通过金属支架的血流可能与血栓栓塞事件有关。
对连续41例使用Pipeline栓塞装置治疗动脉瘤的患者以及78例使用Neuroform支架辅助栓塞的对照组患者进行研究。分析患者病历、手术记录、血小板功能和抗凝状态。在术后多个时间点(术后平均天数[Pipeline栓塞装置/Neuroform]:T1 = 1,T2 = 73/107,T3 = 174,T4 = 277/335,T5 = 409),对系列磁共振图像进行评估,以确定是否存在新出现的扩散加权成像和液体衰减反转恢复(FLAIR)病变。此外,通过病变直径总和估计扩散加权成像或FLAIR负荷。
在所有研究的时间点,使用Pipeline栓塞装置的患者更有可能出现新的同侧FLAIR病变(T = 2时为30.6%,而对照组为7.2%;T = 4时为34.5%,而对照组为6.2%)。使用Pipeline栓塞装置的患者的平均FLAIR负荷显著增加(T = 2时为10.1对0.7 mm,T = 4时为8.8对1.9 mm)。总体而言,34%(14/41)使用Pipeline栓塞装置的患者在任何时候出现新的FLAIR病变,而使用Neuroform支架辅助弹簧圈栓塞的患者为10%(8/78)。术后扩散加权成像不能预测未来的FLAIR病变,提示其原因与手术无关。
Pipeline栓塞装置与延迟出现的新发FLAIR病变发生率增加有关,且与围手术期扩散加权成像病变不同。这些病变的原因和临床影响尚不清楚,提示需要进行谨慎的随访和评估。